Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclofemina is a monthly injectable hormonal contraceptive containing a combination of medroxyprogesterone acetate (a progestogen) and estradiol cypionate (an estrogen). It is used to prevent pregnancy primarily by suppressing ovulation through the inhibition of gonadotropin secretion from the pituitary gland. The formulation is an aqueous suspension intended for intramuscular administration, typically providing effective contraceptive action for one month. In the context of clinical research by Galeno Desenvolvimento de Pesquisas Clínicas, Cyclofemina serves as the reference formulation for bioavailability and safety studies comparing it to other injectable contraceptives such as Depomês.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cyclofemina.